Erythropoietin: Indications and measurement;Erythropoïétine: Quand la prescrire ? Pourquoi et comment la doser ?

Annales de Biologie Clinique

Volumn 67, Issue 5, 2009, Pages 505-515

  Klein, Emilie ^a   Georges, A ^a   Brossaud, J ^a   De Bosredon, K ^a   Bordenave, L ^a   Corcuff, J B ^a  

^a BORDEAUX UNIVERSITY HOSPITAL   (France)

Author keywords

Anaemia; Cancer; Chronic renal failure; Doping; Erythropoietin; Physiology; Polycythemia

Indexed keywords

ERYTHROPOIETIN; RECOMBINANT ERYTHROPOIETIN;

ANEMIA; ARTICLE; CHRONIC KIDNEY FAILURE; DOPING; HUMAN; METABOLISM; NEOPLASM; PHYSIOLOGY; POLYCYTHEMIA; SUBSTANCE ABUSE;

ANEMIA; DOPING IN SPORTS; ERYTHROPOIETIN; ERYTHROPOIETIN, RECOMBINANT; HUMANS; KIDNEY FAILURE, CHRONIC; NEOPLASMS; POLYCYTHEMIA; SUBSTANCE ABUSE DETECTION;

EID: 73949092098     PISSN: 00033898     EISSN: 19506112     Source Type: Journal    
DOI: 10.1684/abc.2009.0356     Document Type: Article

References (28)

1. Jelkmann W. Erythropoietin after a century of research: younger than ever. Eur J Haematol 2007; 78: 183-205.
2. Fisher JW. Erythropoietin: physiology and pharmacology update. Exp Biol Med 2003; 228: 1-14.
3. Ebert BL, Bunn HF. Regulation of the erythropoietin gene. Blood 1999; 94: 1864-77.
4. Bunn HF. New agents that stimulate erythropoiesis. Blood 2007; 109: 868-73.
5. Ng T, Marx G, Littlewood T, Macdougall I. Recombinant erythropoietin in clinical practice. Postgrad Med J 2003; 79: 367-76.
6. Kubatzky KF, Liu W, Goldgraben K, Simmerling C, Smith SO, Constantinescu SN. Structural requirements of the extracellular to transmembrane domain junction for erythropoietin receptor function. J Biol Chem 2005; 280: 14844-54.
7. Sanz Ortiz J. Predictors of response to erythropoiesis-stimulating agents (ESA) in cancer patients: the role of baseline serum epoetin level. Clin Transl Oncol 2008; 10: 486-92.
8. Arcasoy MO. The non-haematopoietic biological effects of erythropoietin. Br J Haematol 2008; 141: 14-31.
9. Hardee ME, Arcasoy MO, Blackwell KL, Kirkpatrick JP, Dewhirst MW. Erythropoietin biology in cancer. Clin Cancer Res 2006; 12: 332-9.
10. Hardee ME, Rabbani ZN, Arcasoy MO, Kirkpatrick JP, Vujaskovic Z, Dewhirst MW, et al. Erythropoietin inhibits apoptosis in breast cancer cells via an Akt-dependent pathway without modulating in vivo chemosensitivity. Mol Cancer Ther 2006; 5: 356-61.
11. Wish JB, Coyne DW. Use of erythropoiesis-stimulating agents in patients with anemia of chronic kidney disease: overcoming the pharmacological and pharmacoeconomic limitations of existing therapies. Mayo Clin Proc 2007; 82: 1371-80.
12. Cazzola M. Erythropoietin therapy: need for rationality and active surveillance. Haematologica 2003; 88: 601-5.
13. Casadevall N. What is antibody-mediated pure red cell aplasia (PRCA) ? Nephrol Dial Transplant 2005; 20 (Suppl. 4): iv3-iv8. (Pubitemid 40711818)
14. Thorpe R, Swanson SJ. Assays for detecting and diagnosing antibody-mediated pure red cell aplasia (PRCA): an assessment of available procedures. Nephrol Dial Transplant 2005; 20 (Suppl 4): iv16- iv22.
15. Casadevall N, Eckardt KU, Rossert J. Epoetin-induced autoimmune pure red cell aplasia. J Am Soc Nephrol 2005; 16 (Suppl 1): S67-9. (Pubitemid 41725087)
16. Shehata N, Walker I, Meyer R, Haynes AE, Imrie K. The use of erythropoiesis-stimulating agents in patients with non-myeloid hematological malignancies: a systematic review. Ann Hematol 2008; 87: 961-73.
17. Beris P. L'érythropoiétine: physiologie et usage clinique. Rev Med Suisse 2000; 58: 159-65.
18. Cazzola M, Mercuriali F, Brugnara C. Use of recombinant human erythropoietin outside the setting of uremia. Blood 1997; 89: 4248-67.
19. Zandecki M. la polyglobulie primitive de Vaquez et les autres polyglobulies. http://www.med.univ-angers.fr/discipline/lab-hema/PATHOL2007/ ERYTHR/17vaquez.pdf.
20. Brière J. Révision des critères diagnostiques de l'OMS pour les PV, TE et MPF: Proposition de nouveaux critères et analyse de la pertinence des précédents. Hématologie 2008; 14: 208-15.
21. Michiels JJ, Bernema Z, Van Bockstaele D, de Raeve H, Schroyens W. Current diagnostic criteria for the chronic myeloproliferative disorders (MPD) essential thrombocythemia (ET), polycythemia vera (PV) and chronic idiopathic myelofibrosis (CIMF). Pathol Biol 2007; 55: 92-104.
22. de Bosredon K, Vuillemin L, Gobinet A, Ducassou D. Erythropoié tine: comparaison de trois trousses de dosage. Rev Fr Lab 2001; 333: 53-5.
23. Marsden JT. Erythropoietin-- measurement and clinical applications. Ann Clin Biochem 2006; 43: 97-104.
24. Mossuz P, Girodon F, Donnard M, Latger-Cannard V, Dobo I, Boiret N, et al. Diagnostic value of serum erythropoietin level in patients with absolute erythrocytosis. Haematologica 2004; 89: 1194-8.
25. Mossuz P, Girodon F, Hermouet S, Dobo I, Lippert E, Donnard M, et al. Serum erythropoietin measured by chemiluminescent immunometric assay: an accurate diagnostic test for absolute erythrocytosis. Clin Chem 2005; 51: 1018-21.
26. Lindstedt G, Lundberg PA. Are current methods of measurement of erythropoietin (EPO) in human plasma or serum adequate for the diagnosis of polycythaemia vera and the assessment of EPO deficiency ? Scand J Clin Lab Invest 1998; 58: 441-58.
27. Segura J, Pascual JA, Gutierrez-Gallego R. Procedures for monitoring recombinant erythropoietin and analogues in doping control. Anal Bioanal Chem 2007; 388: 1521-9.
28. Delanghe JR, Joyner MJ. Testing for recombinant human erythropoietin. J Appl Physiol 2008; 105: 395-6.